<i>Albizia julibrissin</i> Ameliorates Memory Loss Induced by Insomnia in<i> Drosophila</i>

Chang, Jui-Shu; Liu, Hsin-Ping; Cheng, Jack; Chen, Chao-Jung; Hwang, Su-Lun; Tseng, Chi-Chuan; Hsu, Lee-Fen; Lin, Wei-Yong

doi:https://doi.org/10.1155/2019/7395962

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Methods Results Discussion Conclusion Abbreviations Data Availability Conflicts of Interest Authors’ Contributions Acknowledgments Supplementary Materials References Copyright Related Articles

Research Article | Open Access

Volume 2019 | Article ID 7395962 | https://doi.org/10.1155/2019/7395962

Albizia julibrissin Ameliorates Memory Loss Induced by Insomnia in Drosophila

Jui-Shu Chang,¹Hsin-Ping Liu,^2,3Jack Cheng,^1,4Chao-Jung Chen,^1,4Su-Lun Hwang,^5,6Chi-Chuan Tseng,⁷Lee-Fen Hsu,^8,9and Wei-Yong Lin^1,10,4

Academic Editor: Victor Kuete

Received14 Jan 2019

Revised05 Mar 2019

Accepted12 Mar 2019

Published01 Apr 2019

Abstract

In clinical practice in Taiwan, Albizia julibrissin is the most prescribed Chinese herbal medicine for insomnia. Short-term insomnia and hypnotic use both attenuate cognitive functions, especially learning memory. In previous studies, A. julibrissin exhibits sedative activity, antidepressant-like effects, and protection of learning and memory against amnesia. However, whether A. julibrissin ameliorates memory loss caused by short-term sleep deprivation is not clear. We utilized the sleep-deprived Drosophila model and olfactory associative learning-memory assay to test the effects of A. julibrissin on sleep-deprivation induced memory loss. We found that A. julibrissin ameliorated 3-hour memory but not 1-hour memory or instant learning. The findings might be applied to an anticipated short-term sleep disturbance.

1. Introduction

Insomnia dominates the category of sleep disorder and continues to be a rising public problem in recent years, prevalence ranging from 15% to 50% [1]. Although cognitive behavioral therapy for insomnia (CBT-i) is gradually emphasized, as suggested in the 2017 European guideline for the diagnosis and treatment of insomnia as the recommended first-line treatment for chronic insomnia, pharmacological intervention is still indispensable when CBT-i is not available or is not sufficient [2]. Moreover, pharmacological treatment such as benzodiazepines and benzodiazepine receptor agonists are recommended for short-term insomnia [2], with careful management to minimize their drug dependence, including tolerance, escalation of dosage, and a withdrawal syndrome [3]. In practice, the hypnotic use is high (16.2%) in patients visiting their general practitioner [4]. However, the increased risk for dementia and fractures was associated with the use of hypnotics for insomnia as revealed in a meta-analysis [5].

Besides, sleep disturbance itself causes cognitive deficits. Interestingly, different types of sleep problems lead to distinct profiles of the disturbed domain of cognition [6]. Since short-term sleep deprivation (i.e., 1-2 nights) but not long-term insomnia causes deficits in attention and memory [6], an investigation into assisting with memory problems due to short-term sleep disruption is necessary.

In clinical practice of Taiwan, 87% of patients with sleep disorder take “Western” medicine, while 12% of them take Chinese herbal medicine [7]. Albizia julibrissin is one of the most common individual Chinese herbs consumed for insomnia and occupies 10% of the prescription, included as a component in the compound formula (Fu-Fang, regimen, or remedy) in Taiwan [8]. In traditional Chinese medicine (TCM) practice, A. julibrissin is also prescribed for liver depression and qi stagnation [9]. In preclinical studies, A. julibrissin exhibits sedative activity [10, 11], anxiolytic effects [12, 13], and antidepressant-like effects [14]. Moreover, A. julibrissin treatment in mice shortened sleeping onset time and prolonged sleep duration time [11, 15] and protected learning and memory against amnesia induced by scopolamine [16]. Due to these cues, we hypothesized that A. julibrissin ameliorates memory loss caused by short-term insomnia or sleep deprivation.

In the field of sleep and circadian rhythms, discoveries in Drosophila melanogaster model (fruit flies) have led the fundamental breakthroughs and are found to be conserved in the mammal, including identification of first core clock gene and mechanism for photic resetting [17]. As a tool to study learning memory, olfactory learning of Drosophila shares the same characteristics of Pavlovian learning with other animals, including acquisition, extinction, conditioned excitation, and conditioned inhibition [18]. Furthermore, Drosophila shares similar molecular pathway with the mammal for memory storage, such as cAMP-PKA-CREB [19].

The recommended dosage of the extracted A. julibrissin is 3~6 g each time for an adult according to the Taiwan Herbal Pharmacopoeia [20], and the usual prescription of three times per day leads to a daily dose of 9~18 g, which is equivalent to 4.5~9 mg/ml approximately. In this study, we evaluated the efficacy of A. julibrissin treatment, with two doses of 4.5 and 18 mg/ml, on the learning and memory of sleep-deprived Drosophila model.

2. Methods

2.1. Maintenance of Drosophila and Sleep Deprivation

Canton-S is obtained from Bloomington Drosophila Stock Center and maintained with cornmeal-sucrose-yeast culture medium under 12h day-night shift at 25°C. For evaluating the impact of disturbance on learning and memory, flies at the age of 5 to 7 day after emergence were used. For assessing the effect of protection of A. julibrissin treatment on learning and memory disturbed by sleep deprivation, flies were treated with A. julibrissin of different concentrations, i.e., 0, 4.5, and 18 mg/ml, for 5 days since emergence and subjected to sleep deprivation at the night of the day for 12h, and then subjected to T-maze for olfactory associative learning at the day. For sleep deprivation, Drosophila culture bottles were fixed on the orbital shaker (VWR VX2500) at 850 rpm during ZT 13-24. The culture bottles of the control were placed at the same space.

2.2. Preparation of Albizia julibrissin

Fresh flowers of A. julibrissin (6 kg) were boiled with water (6 liters) for 1hr, filtered out precipitant, water bathed and concentrated to 150 ml, and freeze-dried to 90 g powder. The powder was added to and mixed thoroughly with a food processor in the Drosophila culture medium before solidification. The final concentration of A. julibrissin powder in culture medium was 4.5 and 18 mg/ml.

2.3. Profiling of Extract by LC-ESI-Q-TOF

For the quality control of A. julibrissin extracts, spectrometry was undertaken. An ultra-high performance liquid chromatography (UHPLC) system (Ultimate 3000; Dionex, Germany) equipped with a C18 reversed-phase column (2.1 × 150 mm, 3 μm, T3; Waters, Milford, MA, USA) was coupled with a hybrid Q-TOF mass spectrometer (maXis impact, Bruker Daltonics, Bremen, Germany) with an orthogonal electrospray ionization (ESI) source. A volume of 2 μL of sample was injected. The LC flow rate was 0.20 mL/min. At the beginning of elution, 100% solvent A (0.1% formic acid) was used, and then the solvent B (acetonitrile with 0.1% formic acid) was increased to 60% during a span of 17 min and finally to 100% over a period of 0.1 min after which this percentage composition was held for 1.9 min. After 0.1 min, solvent B was reduced back down to 0% and held at this percentage for 3.9 min. The mass spectrometer was operated in either positive or negative ion mode using the m/z range 50~1000 at 1 Hz. The capillary voltage of the ion source and negative was set at +4200 V for the positive mode. The nebulizer gas flow was 1 bar and drying gas flow was 8 L/min. The drying temperature was set at 200°C. The HPLC fingerprint for quality control of A. julibrissin powder is shown in Supplementary Figure 1.

2.4. Olfactory Associative Learning-Memory Assay (T-Maze)

The training session was performed according to a previous study [21]. Briefly, approximately 100 flies were exposed sequentially to two odors, either 18 μM of 3-octanol (OCT) or 13 μM of 4-methylcyclohexanol (MCH). One biological replicate contains two bottles of flies for these two odors, respectively. Flies exposed to the first odor were simultaneously supplied with 80~90 V electric shocks and then received a second odor control group without electric shocks. Learning ability was determined immediately after training, while 1-h or 3-h memory was determined after 1 or 3 h after training. To perform the test, the trained flies were loaded into the choice point of a T-maze in which they were exposed simultaneously to OCT and MCH. A performance index (PI) was calculated to represent the conditioned odor avoidance. The biological replicates are indicated in Figures 1(a), 2(a), 2(b), and 3.

(a)

(b)

(a)

(b)

Figure 2

A. julibrissin ameliorated sleep-deprivation induced 3-h memory impairment. (a) The performance index showing 1 h memory of Drosophila. All doses of A. julibrissin did not rescue the impairment induced by sleep deprivation. (b) The performance index showing 3 h memory of Drosophila. High dose of A. julibrissin rescued the impairment induced by sleep deprivation. “SDF” denotes sleep-deprived flies, while “NSD” denotes non-sleep-deprived control. Doses of A. julibrissin are in mg/ml. # denotes p < 0.05 compared to SDF by one-way ANOVA and post hoc Dunnett’s multiple comparisons test. denotes p < 0.05 compared to NSD by Student’s T-test. Error bar stands for the standard error of the mean.

2.5. Statistics

To evaluate the effect of disturbance on learning and memory, the significance of the difference between performance indexes of flies with and without sleep deprivation was calculated with Student’s T-test. To evaluate the effect of protection of A. julibrissin treatment on learning and memory disturbed by sleep deprivation, one-way ANOVA and post hoc Dunnett’s multiple comparisons test was applied. The p value < 0.05 was considered significant.

3. Results

3.1. Sleep Deprivation Impaired 1-h and 3-h Memory of Drosophila

To test our hypothesis that A. julibrissin ameliorates memory loss caused by short-term insomnia or sleep deprivation by using Drosophila model, as an internal control, we have had to show that sleep deprivation impairs memory and to determine which type of memory is influenced in advance. The control experiment program is showed in Figure 1(a). Flies of the age of 5 ~ 7 days after emergence, without A. julibrissin treatment, were sleep deprived for one night (the SDF group) or not sleep deprived (the NSD group) at the day just before memory test and were subjected to olfactory associative learning (T-maze) assay to evaluate instant learning, 1-h memory, and 3-h memory. As shown in Figure 1(b), sleep deprivation impaired 1-h and 3-h memory, but not instant learning of Drosophila.

3.2. A. julibrissin Pretreatment Ameliorated Sleep-Deprivation Induced 3-h Memory Impairment

Next, we tested whether pretreatment of A. julibrissin protects memory against sleep deprivation. Emerged flies were divided into three groups of A. julibrissin treatment with different concentrations, i.e., 0, 4.5, and 18 mg/ml, for five days and were subjected to sleep deprivation for one night. At the next day after sleep deprivation, flies were subjected to olfactory associative learning-memory assay (T-maze) for 1-h memory and 3-h memory tests. As shown in Figure 2(a), A. julibrissin treatment did not improve 1-h memory. However, A. julibrissin of high concentration (18mg/ml) protected 3-h memory against sleep deprivation (Figure 2(b) and Tables 1 and 2).

3.3. A. julibrissin Did Not Alter Learning and Memory of Drosophila without Sleep Deprivation

To rule out that the effect of pretreatment of A. julibrissin is a confounding result from its ability to elevate memory capacity rather than its protection against sleep deprivation, we tested the memory of flies with A. julibrissin treatment but without sleep deprivation. Emerged flies were divided into three groups of A. julibrissin treatment with different concentrations, i.e., 0, 4.5, and 18 mg/ml, for five days and were subjected to olfactory associative learning-memory assay (T-maze) for instant learning, 1-h memory, and 3-h memory tests. As shown in Figure 3, instant learning, 1-h memory, and 3-h memory were not significantly altered with A. julibrissin treatment. Therefore, we confirmed that A. julibrissin pretreatment ameliorates 3-h memory impairment by sleep deprivation, but not elevating memory capacity.

4. Discussion

In this study, we utilized Drosophila as the model of memory impairment by sleep disruption and justified our hypothesis that A. julibrissin ameliorates sleep-deprivation induced memory impairment. Our data showed that sleep deprivation impairs 1-h and 3-h memory but not the instant learning ability of Drosophila, which is consistent with the previous study [22]. With A. julibrissin treatment, only 3-h memory but not 1-h memory of sleep-deprived Drosophila was rescued. To the best of our knowledge, this is the first demonstration that A. julibrissin treatment rescues memory loss impaired by insomnia in an animal model.

The limitations of this study include that (1) only young subjects (5 days after emergence) were tested, and the findings cannot be extended directly to elderly subjects, who are more vulnerable to sleep deprivation [23]. (2) Only short-term sleep disturbance (one night) was tested. However, unlike short-term insomnia, the impact of chronic insomnia on memory is not significant [6]. Therefore, we omitted the test of chronic insomnia in this study. (3) We used the mixture of water extractables rather than a specific compound of A. julibrissin. Further studies to identify the most effective compound are essential for therapeutic development. (4) We did not perform cotreatment with other hypnotics, such as benzodiazepines, to confirm whether hypnotics interferes the protection to memory against sleep deprivation by A. julibrissin. (5) The treatment was given before sleep deprivation, which may imply the clinical application to be preventive, but not curative.

Phytochemical studies revealed different classes of secondary metabolites in genus Albizia, like triterpene saponins, flavonoids, and alkaloids [24]. Since flavonoids and alkaloids dissolve poorly in water, we suggest saponins from A. julibrissin to be the bioactive component for the effect against memory loss due to sleep disruption. However, this report does not rule out the possibility that flavonoids or alkaloids from A. julibrissin to be effective in the same scenario. Since the discovery of the first saponin julibroside J1 at 1996 [25], many julibrosides, including julibroside J1, JC1, J2, J3, J4, J5, J8, J9, J14, J15, J16, J20, J22, J25, J28, J29, J30, J31, and J35, and their isomers have been identified in A. julibrissin [26]. Among these saponins, some phytomedical characteristics have been determined, i.e., cytotoxicity for J1 to J3 [27] and J21 [28], antiangiogenicity for J8 [29], antitumor activity for J28 [30], J29, J30, and J31 [31], and anxiolytic-like effects for JC1 [13]. JC1 seems to contribute to the anti-insomnia effect of A. julibrissin, but which saponin(s) dominate the effect against memory loss due to sleep deprivation requires further investigation.

Although we did not study the underlying mechanism, previous studies of A. julibrissin have identified its effects on neural transmission. Aqueous extract of A. julibrissin increases 5-HT1A receptors in serotonergic neurons in the frontal cortex and hippocampus of rat brain [32]. Moreover, A. julibrissin shows antidepressant effects possibly through antagonizing the neuron apoptosis of hippocampus [33]. Furthermore, A. julibrissin prevents apoptosis in neurons from oxidative stress [34]. These studies together suggest that A. julibrissin protects neuron from oxidative stress, which may be induced by short-term insomnia [35].

Despite these limitations, this study breaks Chinese alternative medicine (CAM) into a specific herb, whereas normally CAM contains grouped herbs into one treatment [36]. Although the compound formula (Fu-Fang, regimen, or remedy) in CAM is well established in Chinese medicine tradition, the decomposition of the compound formula into a specific herb or even into a bioactive molecule may modernize CAM as a resource of drug development.

5. Conclusion

We found that A. julibrissin treatment ameliorated memory loss induced by sleep deprivation in Drosophila model. The findings in this study might be applied to an anticipated short-term sleep disturbance, such as a temporary night shift, stay up late for an exam, or jet lag. In the future study, we will focus on (1) side effects of long-term treatment, (2) using older subjects, (3) extracted compounds, and (4) comparison and cotreatment with hypnotic for A. julibrissin on insomnia. In conclusion, this is an innovative study that may provide a new pharmacological treatment to aid in protecting memory loss in individuals with short-term sleep loss.

Abbreviations

SDF:	Sleep-deprived flies
NSD:	Non-sleep-deprived flies
A. julibrissin:	Albizia julibrissin
CBT-i:	Cognitive behavioral therapy for insomnia
OSA:	Obstructive sleep apnea
TCM:	Traditional Chinese medicine
OCT:	3-octanol
MCH:	4-methylcyclohexanol
PI:	Performance index
CAM:	Chinese alternative medicine.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Jui-Shu Chang (crscmh123@yahoo.com.tw) and Hsin-Ping Liu (hpliu@mail.cmu.edu.tw) designed the study and proofed the paper. Jack Cheng (t91917@mail.cmuh.org.tw) wrote the manuscript and performed statistical analysis. Chao-Jung Chen (cjchen@mail.cmu.edu.tw) wrote the manuscript and performed LC-ESI-Q-TOF. Su-Lun Hwang (slhuang@gw.cgust.edu.tw) and Chi-Chuan Tseng (wellness@cgmh.org.tw) performed the experiments. Lee-Fen Hsu and Wei-Yong Lin supervised the experiments and revised the manuscript. All the authors read and approved the final manuscript. Jui-Shu Chang and Hsin-Ping Liu contributed equally to this work.

Acknowledgments

This work was supported by grants from the Ministry of Science and Technology (MOST 104-2320-B-039-009, MOST 106-2320-B-039-023, MOST 106-2632-B-039-001, and MOST 107-2314-B-039-042-MY2) and grants from China Medical University & Hospital (CMU102-BC-7, DMR-101-065, DMR-103-099, CMU104-S-14-03, CMU107-S-51, and CMU107-S-08). This study is also supported in part by the Chang Gung Memorial Hospital (Grants CMRPF6D0051, CMRPF6D0052, and CMRPF6D0053).

Supplementary Materials

The HPLC fingerprint for quality control of A. julibrissin. (Supplementary Materials)

References

X. Cao, S. Wang, B. Zhong et al., “The prevalence of insomnia in the general population in China: A meta-analysis,” PLoS ONE, vol. 12, no. 2, p. e0170772, 2017.
View at: Publisher Site | Google Scholar
D. Riemann, C. Baglioni, C. Bassetti et al., “European guideline for the diagnosis and treatment of insomnia,” Journal of Sleep Research, vol. 26, no. 6, pp. 675–700, 2017.
View at: Google Scholar
H. Ashton, “The diagnosis and management of benzodiazepine dependence,” Current Opinion in Psychiatry, vol. 18, no. 3, pp. 249–255, 2005.
View at: Publisher Site | Google Scholar
B. Bjorvatn, E. Meland, E. Flo, and T. Mildestvedt, “High prevalence of insomnia and hypnotic use in patients visiting their general practitioner,” Journal of Family Practice, vol. 34, no. 1, pp. 20–24, 2017.
View at: Publisher Site | Google Scholar
T. J. Wilt, R. MacDonald, M. Brasure et al., “Pharmacologic treatment of insomnia disorder: An evidence report for a clinical practice guideline by the American college of physicians,” Annals of Internal Medicine, vol. 165, no. 2, pp. 103–112, 2016.
View at: Publisher Site | Google Scholar
M. Olaithe, R. S. Bucks, D. R. Hillman, and P. R. Eastwood, “Cognitive deficits in obstructive sleep apnea: Insights from a meta-review and comparison with deficits observed in COPD, insomnia, and sleep deprivation,” Sleep Medicine Reviews, vol. 38, pp. 39–49, 2018.
View at: Publisher Site | Google Scholar
Y.-L. Chen, C.-Y. Lee, K.-H. Huang, Y.-H. Kuan, and M. Chen, “Prescription patterns of Chinese herbal products for patients with sleep disorder and major depressive disorder in Taiwan,” Journal of Ethnopharmacology, vol. 171, pp. 307–316, 2015.
View at: Publisher Site | Google Scholar
F.-P. Chen, M.-S. Jong, Y.-C. Chen et al., “Prescriptions of Chinese herbal medicines for insomnia in Taiwan during 2002,” Evidence-based Complementary and Alternative Medicine, vol. 2011, Article ID 236341, 9 pages, 2011.
View at: Publisher Site | Google Scholar
W.-F. Yeung, K.-F. Chung, K.-Y. Ng et al., “Prescription of chinese herbal medicine in pattern-based traditional chinese medicine treatment for depression: a systematic review,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 160189, 12 pages, 2015.
View at: Publisher Site | Google Scholar
T. H. Kang, S. J. Jeong, N. Y. Kim, R. Higuchi, and Y. C. Kim, “Sedative activity of two flavonol glycosides isolated from the flowers of Albizzia julibrissin Durazz,” Journal of Ethnopharmacology, vol. 71, no. 1-2, pp. 321–323, 2000.
View at: Publisher Site | Google Scholar
W.-J. Yang and Y.-Z. Fan, “Experimental study on sedative and hypnotic effect of the leaf of albizia julibrissin durazz in mice,” Lishizhen Medicine and Materia Medica Research, vol. 9, 2008.
View at: Google Scholar
W.-K. Kim, J. W. Jung, N. Y. Ahn et al., “Anxiolytic-like effects of extracts from Albizzia julibrissin bark in the elevated plus-maze in rats,” Life Sciences, vol. 75, no. 23, pp. 2787–2795, 2004.
View at: Publisher Site | Google Scholar
Y.-H. Jung, R.-R. Ha, S.-H. Kwon et al., “Anxiolytic effects of Julibroside C1 isolated from Albizzia julibrissin in mice,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 44, pp. 184–192, 2013.
View at: Publisher Site | Google Scholar
J.-H. Kim, S. Y. Kim, S.-Y. Lee, and C.-G. Jang, “Antidepressant-like effects of Albizzia julibrissin in mice: involvement of the 5-HT1A receptor system,” Pharmacology Biochemistry & Behavior, vol. 87, no. 1, pp. 41–47, 2007.
View at: Publisher Site | Google Scholar
S.-M. Cho, M. Shimizu, C. J. Lee et al., “Hypnotic effects and binding studies for GABAA and 5-HT2C receptors of traditional medicinal plants used in Asia for insomnia,” Journal of Ethnopharmacology, vol. 132, no. 1, pp. 225–232, 2010.
View at: Publisher Site | Google Scholar
K. Dhanya, S. Satish, K. Hegde, and A. Shabaraya, “Investigation on learning and memory enhancing activity of essential oil in Albizia julibrissin flowers in experimental mice,” Asian Journal of Biomedical and Pharmaceutical Sciences, vol. 6, no. 55, 2016.
View at: Google Scholar
J. C. Hendricks, “Invited review: Sleeping flies don't lie: The use of Drosophila melanogaster to study sleep and circadian rhythms,” Journal of Applied Physiology, vol. 94, no. 4, pp. 1660–1672, 2003.
View at: Publisher Site | Google Scholar
C. Margulies, T. Tully, and J. Dubnau, “Deconstructing memory in Drosophila,” Current Biology, vol. 15, no. 17, pp. R700–R713, 2005.
View at: Publisher Site | Google Scholar
B. Milner, L. R. Squire, and E. R. Kandel, “Cognitive neuroscience and the study of memory,” Neuron, vol. 20, no. 3, pp. 445–468, 1998.
View at: Publisher Site | Google Scholar
T. H. P. Commission, Taiwan Herbal Pharmacopoeia, Ministry of Health and Welfare, Taiwan, 2013.
J. Dubnau, L. Grady, T. Kitamoto, and T. Tully, “Disruption of neurotransmission in Drosophila mushroom body blocks retrieval but not acquisition of memory,” Nature, vol. 411, no. 6836, pp. 476–480, 2001.
View at: Publisher Site | Google Scholar
X. Li, F. Yu, and A. Guo, “Sleep deprivation specifically impairs short-term olfactory memory in Drosophila,” SLEEP, vol. 32, no. 11, pp. 1417–1424, 2009.
View at: Publisher Site | Google Scholar
M. J. Barker, K. M. Greenwood, M. Jackson, and S. F. Crowe, “Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis,” Archives of Clinical Neuropsychology, vol. 19, no. 3, pp. 437–454, 2004.
View at: Publisher Site | Google Scholar
K. Kokila, S. D. Priyadharshini, and V. Sujatha, “Phytopharmacological properties of Albizia species: a review,” Int J Pharm Pharm Sci, vol, vol. 5, no. 3, pp. 70–73, 2013.
View at: Google Scholar
L. Ma, G. Tu, S. Chen et al., “NMR determination of the structure of Julibroside J1,” Carbohydrate Research, vol. 281, no. 1, pp. 35–46, 1996.
View at: Publisher Site | Google Scholar
L. Han, G. Pan, Y. Wang et al., “Rapid profiling and identification of triterpenoid saponins in crude extracts from Albizia julibrissin Durazz. by ultra high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 55, no. 5, pp. 996–1009, 2011.
View at: Publisher Site | Google Scholar
T. Ikeda, S. Fujiwara, K. Araki, J. Kinjo, T. Nohara, and T. Miyoshi, “Cytotoxic glycosides from Albizia julibrissin,” Journal of Natural Products, vol. 60, no. 2, pp. 102–107, 1997.
View at: Publisher Site | Google Scholar
K. Zou, Y.-Y. Zhao, and R.-Y. Zhang, “A cytotoxic saponin from Albizia julibrissin,” Chemical & Pharmaceutical Bulletin, vol. 54, no. 8, pp. 1211-1212, 2006.
View at: Publisher Site | Google Scholar
H. Hua, L. Feng, X.-P. Zhang, L.-F. Zhang, and J. Jin, “Anti-angiogenic activity of julibroside J8, a natural product isolated from Albizia julibrissin,” Phytomedicine, vol. 16, no. 8, pp. 703–711, 2009.
View at: Publisher Site | Google Scholar
H. Liang, W.-Y. Tong, Y.-Y. Zhao, J.-R. Cui, and G.-Z. Tu, “An antitumor compound julibroside J28 from Albizia julibrissin,” Bioorganic & Medicinal Chemistry Letters, vol. 15, no. 20, pp. 4493–4495, 2005.
View at: Publisher Site | Google Scholar
L. Zheng, J. Zheng, Y. Zhao, B. Wang, L. Wu, and H. Liang, “Three anti-tumor saponins from Albizia julibrissin,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 10, pp. 2765–2768, 2006.
View at: Publisher Site | Google Scholar
J. W. Jung, J.-H. Cho, N. Y. Ahn et al., “Effect of chronic Albizzia julibrissin treatment on 5- hydroxytryptamine1A receptors in rat brain,” Pharmacology Biochemistry & Behavior, vol. 81, no. 1, pp. 205–210, 2005.
View at: Publisher Site | Google Scholar
C.-f. Guo, M. Xia, S.-g. Yin, and X.-l. Shi, “Antidepressant effect by albizzia julibrissin flower total flavonoids and its mechanism,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 13, p. 67, 2013.
View at: Google Scholar
S. H. Kwon, S. I. Hong, S. X. Ma, S. Y. Lee, and C. G. Jang, “3′,4′,7-trihydroxyflavone prevents apoptotic cell death in neuronal cells from hydrogen peroxide-induced oxidative stress,” Food and Chemical Toxicology, vol. 80, pp. 41–51, 2015.
View at: Publisher Site | Google Scholar
R. H. Silva, V. C. Abílio, A. L. Takatsu et al., “Role of hippocampal oxidative stress in memory deficits induced by sleep deprivation in mice,” Neuropharmacology, vol. 46, no. 6, pp. 895–903, 2004.
View at: Publisher Site | Google Scholar
M. J. Leach and A. T. Page, “Herbal medicine for insomnia: A systematic review and meta-analysis,” Sleep Medicine Reviews, vol. 24, pp. 1–12, 2015.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2019 Jui-Shu Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies